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Beta site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors hold great potential as disease
modifying anti-Alzheimer’s drugs. This digest provides an overview of the amidine containing class of
BACE1 inhibitors, of which multiple examples are now progressing through clinical trials. The various
structural modiﬁcations highlight the struggle to combine potency with the optimal properties for a brain
penetrant BACE1 inhibitor, and illustrate the crowded competitive landscape. This overview concludes
with a summary of potential issues including substrate and target selectivity and a synopsis of the status
of the current and past clinical assets.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Alzheimer’s disease (AD) has clearly identiﬁed itself as an insid-
ious disease, which chronically ravages the cognitive capabilities of
the sufferer, resulting in gradual decline in cognition, memory and
changes in behavior which inevitably lead to death. With the
demographic shift towards an aging population, resulting in an in-
creased number of patients, this disease is fast becoming a serious
economic and social burden.
AD is characterized by the existence of two pathological fea-
tures namely amyloid plaques and neuroﬁbrillary tangles. The
observation of these features has led to the development of the
amyloid cascade hypothesis.1 Two decades have passed since this
hypothesis was initially postulated and during this time it has been
analyzed and modiﬁed.2,3 The amyloid cascade hypothesis is based
on a culmination of genetic and histopathological data, which sug-
gest that AD is a direct consequence of the presence of amyloid-b
(Ab) aggregates in the brain.4 Initially, the Ab plaques were be-
lieved to be the only toxic component, but this hypothesis was la-
ter reﬁned to incorporate a dual effect: The Ab oligomers are
believed to cause damage to the neurons, particularly, the neuronal
synapses. This neurotoxicity then leads to a cascade of events
including tau hyperphosphorylation and tau neuroﬁbrillary tangle
formation.5
To date, the amyloid cascade hypothesis remains polemic as it
has not been fully validated,3 but still represents a widely sup-
ported theory, substantiated by genetic evidence from the various
mutations of amyloid precursor protein (APP). Up until now, about
30 mutations of APP have been identiﬁed; of these, 25 arepathogenic, resulting in a higher incidence of early onset AD
(EOAD).6 Recently, the ﬁrst AD protective mutation of APP, the
A673T mutant, was identiﬁed.7 The mutation of alanine-673 to
threonine, leads to an APP analog that is a 50% less efﬁcient sub-
strate for BACE1, than wild type APP. This mutation is responsible
for not only increasing the chance of reaching 85 years of age with-
out suffering from AD by 50%, but for also slowing the natural cog-
nitive decline in the elderly. Interestingly, due to the fact that APP
is quite a poor substrate for BACE1, most amino-acid mutations
close to the cleavage site of APP result in faster proteolysis and in-
creased rate of disease progression. This ﬁnding has further rein-
forced the amyloid cascade hypothesis and suggests that BACE1
maybe the therapeutic target of choice when developing disease
modifying anti-Alzheimer’s drugs.7–9
BACE1, a 501 amino acid integral membrane aspartyl protease
was discovered in 1999,10 and is the rate limiting enzyme for the
formation of Ab.11 BACE2,12 identiﬁed shortly after BACE1, shares
64% sequence homology with BACE1 and has been shown to be
expressed primarily in the periphery, while BACE1 is mainly
expressed in the neurons. BACE1 is predominantly active at pH
4.5–5.5 within the acidic environment of the endosomes.
In 1999, Sinha et al. at Elan Pharmaceuticals successfully puri-
ﬁed BACE1 from human brain using a substrate analog which
exhibited a statine residue as a transition state analog. Further to
that, they also successfully cloned the BACE1.13 The ﬁrst X-ray
crystal structure of a complex between recombinant BACE1 and
the OM99-2 inhibitor was achieved a few years later by Ghosh
and Tang.14 This initial work established BACE1 as a target and
the initial X-ray crystal structure aided subsequent medicinal
chemistry investigations.
Figure 2.
2034 D. Oehlrich et al. / Bioorg. Med. Chem. Lett. 24 (2014) 2033–2045During the last two decades many potent BACE1 inhibitors have
been described but few have successfully displayed balanced
in vitro potency and the necessary PK properties/parameters to
achieve in vivo efﬁcacy. The initial examples of BACE1 inhibitors,
like most inhibitors of aspartate proteases, originated from sub-
strate and transition state analog-based design. This development
resulted in large polar compounds with high total polar surface
area (TPSA), exhibiting many rotatable bonds and numerous
hydrogen bond donor (HBD) and hydrogen bond acceptors (HBA),
making them prohibitive for permeability especially through the
blood brain barrier (BBB), a prerequisite for CNS active com-
pounds.15 Further to the physiochemical properties that prevented
cell penetration, many classes of substrate and transition state de-
rived inhibitors exhibited permeability glycoprotein (Pgp) efﬂux
activity, adding to the reduced central penetration/exposure.16
The identiﬁcation, research progress and development of BACE1
inhibitors has been discussed in several recent reviews.17–19
Due to the large size of the catalytic active site, the search for
non-peptidomimetic BACE1 inhibitors and their optimization has
proved to be very challenging. Among the non-peptidomimetic
scaffolds, amidine- or guanidine-containing heterocycles were
identiﬁed early on via fragment based screening to form an ideal
hydrogen-bonding network with the catalytic aspartyl dyad of
BACE. In 2005, patent applications from both Schering–Plough
and Wyeth disclosed 5,5-disubstituted aminohydantoins, exempli-
ﬁed by generic structure 1 (Fig. 1).20,21 In addition to the interaction
with the catalytic aspartates, the 5,5-disubstituted sp3 carbon pro-
vided for an optimal vector into the P1 and P20 pockets, as apparent
from co-crystal structures with BACE1.22,23 The combination of
amidine containing warheads with optimal substitution vectors
has led to a series of BACE1 inhibitor with high ligand efﬁciency.
Since 2005, many companies have elaborated and expanded on
this motif, overcoming the obstacles towards safe and centrally
efﬁcacious BACE1 inhibitors. During the rest of this digest we will
concentrate our efforts on describing the development of this most
promising generation of BACE1 inhibitors, which fall under the
scope of the general structure shown in Figure 2. Multiple com-
pounds from this class have now advanced into the clinic, and
we will conclude with an overview of the known status of these
studies.
Since BACE1 is active at a pH of between 4.5 and 5.5 and resides
within the acidic intracellular compartments, BACE1 inhibitors not
only need to reach the site of action, but they also need to be opti-
mally protonated to efﬁciently inhibit the enzyme. Many groups
have identiﬁed the importance of pKa when designing potent cell
penetrant BACE1 inhibitors.24,25
The amidine containing subclasses of BACE1 inhibitors were
identiﬁed using both HTS and fragment based drug discovery.
The hits from Eli Lilly (3 & 4), AstraZeneca (5) and Schering–Plough
(2) were all discovered by means of fragment screens using
different techniques to optimally identify the weakly activeN P1
1
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P2'
P1'
R
F
NH 2
N
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Figure 1.fragments, including NMR, SPR as well as in vitro assays.19,26,27 In
contrast, Wyeth (6) and Roche (7) identiﬁed their hits through
more traditional HTS campaign.22,28 This warhead was also
exploited by both Shionogi and Eli Lilly,29 where the latter com-
pany arrived at this warhead via a fragment-based approach.30
AstraZeneca further reﬁned their aminopyrimidinone BACE1
inhibitor hit 5 by screening related structures from their corporate
compound collection, identifying potent analogue 8 with a phen-
ethyl substituent (Fig. 4).26 X-ray analysis revealed that the ethyl
linker was key to optimally ﬁlling the P1/P3 pocket. In a collabo-
rated effort with Astex Therapeutics, they identiﬁed compound 9.31
Shionogi later investigated the possibility of constraining the
ﬂexible ethyl linker of 9 by introducing a cyclopropane.32,33 Their
analogues 10 and 11 exhibited an unexpected binding mode in
which the cyclopropane ring forms CH-p interaction with Tyr71
side chain of the enzyme. Nevertheless, no improvement in po-
tency was achieved over 9 (Fig. 5).31
Wyeth analyzed their 8,8-disubstituted-tetrahydroimidazo-
pyrimidin-6-amine fragment hit 6 using an X-ray crystal structure
of their hit bound to BACE1. The structure revealed that the guani-
dine moiety forms key H-bonds with the catalytic aspartic acid res-
idues Asp32 and Asp228.22,23 The tetrahydropyrimidine ring points
towards the solvent and gives no additional interactions with the
enzyme. Consequently, truncation of this system resulted in the
identiﬁcation of the smaller 2-amino-3-methyl-5,5-diphenylhy-
dantoin 12 with 10-fold higher potency (Fig. 6).22 The increase in
potency observed between 6 and 12 is attributed to the strength
and capabilities of each compound to form the necessary H-bond
with the catalytic site aspartate residues, which is rationalized by
the pKa of the system (6, pKa = 5.7 vs 12, pKa = 7.6).22 The initial
investigation was focused towards modiﬁcations that optimally
ﬁlled the P1, P3 and P20 pockets; as a result, inhibitors 13 and 14
with more than 1000-fold increase in binding afﬁnity over the
hit 6 were identiﬁed. A key ﬁnding was the identiﬁcation that
meta-substitution of P1 phenyl ring by pyridine or pyrimidine
would allow an optimal vector into the P3 pocket, with the nitro-
gen atoms of the heteroaromatics forming a water mediated
H-bridge with Ser229. Since then, this substitution pattern has been
applied in many R&D programs. In the P20 pocket, substitution of
the phenyl ring of 12 with para-methoxy or triﬂuoromethoxy
group gave an additional increase in potency by generating a
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D. Oehlrich et al. / Bioorg. Med. Chem. Lett. 24 (2014) 2033–2045 2035hydrogen-bond interaction with the Trp67 residue of the BACE1 en-
zyme. The ability of the compound 13 to reduce Ab in vivo was
evaluated and its lack of efﬁcacy was attributed to its low brain
exposure.22 To improve brain permeability and in vivo efﬁcacy of
this aminohydantoin series, several physicochemical parameters
(size, polarity, metabolic stability, Pgp afﬁnity) were studied by
Wyeth, resulting in compound 16.34 Selectivity of BACE1 over
BACE2, was also explored by further exploration of the P20 pocket,
where the Pro70 of BACE1 is replaced by Lys86 in BACE2. The ob-
served changes in selectivity were attributed to the differences in
amino-acid as well as the changes in dynamics of the ﬂap between
the two enzymes.22 One of the most selective compounds, 15 is
shown in Figure 6, displaying a 670-fold preference for BACE1 ver-
sus BACE2 and even higher selectivity for cathepsin D, pepsin and
renin (Fig. 6).35
Array BioPharma and Genentech followed a structure-based de-
sign approach when developing their potent and brain penetrant
aminohydantoin inhibitors. They conformationally constrained
the system using spirocyclic aminohydantoins, identifying BACE1
inhibitor 17 with an IC50 of 48 nM and cellular activity of 27 nM
(Fig. 7).36,37 This was an analogous exploration to that previously
performed by Wyeth, exempliﬁed by 20.38 Although compound
17 was able to cross the BBB, it suffered from very high Pgp med-
iated efﬂux. Further optimization of BACE1 potency was achieved
by expanding the molecule into the P20 pocket which resulted in16, BACE1 IC50 = 20 nM
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Figure 7.
2036 D. Oehlrich et al. / Bioorg. Med. Chem. Lett. 24 (2014) 2033–2045the identiﬁcation of novel inhibitors 18 with sub-nanomolar afﬁn-
ity for BACE1 (Fig. 7).39,40 Similar spiro-2-aminohydantoins and
their six-membered analogues 2-amino-dihydropyrimidinones23, BACE1 IC
Cell pIC50 = 7.
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Figurewere also published and investigated by Amgen, exempliﬁed by
19.41 Vitae Pharmaceuticals described several analogous series of
double spiro systems, represented by 21.42
Interestingly, AstraZeneca followed a scaffold hopping protocol
from dihydroisocytosine to aminohydantoin which ﬁnally identi-
ﬁed a series of bicyclic aminoimidazoles similar to the HTS hit pre-
viously described by Wyeth (6) (Fig. 3).22,43 Aminoimidazole 22
(Fig. 8) displayed low permeability particularly through the BBB
which was attributed to the high basicity of the amino-imidazole
warhead (calculated pKa >8). It was rationalized that lowering
the pKa would be beneﬁcial for permeability, as at the physiological
pH, the molecule is highly protonated and as such not membrane
permeable. Modiﬁcation of the pKa was achieved by adding elec-
tron-withdrawing groups, such as ﬂuorines; this resulted in the
identiﬁcation of 23 with a pKa of 5.3. This modiﬁcation resulted
in improved permeability; however the compounds still suffered
from a high Pgp efﬂux liability. Further modiﬁcations resulted in
the identiﬁcation of 24 with reasonable permeability and efﬂux
in vitro. The in vitro result however did not correlate to that
observed in vivo. To understand this discrepancy, 24 was co-
administered with the Pgp inhibitor elacridar, which highlighted
the still severe efﬂux liability of the compound.43,44
In addition to the amino-imidazole series, AstraZeneca evalu-
ated amino-isoindoles as BACE1 inhibitors.43 Introduction of a
ﬂuorine atom ortho to the amidine was key in achieving an optimal
pKa, permeability and efﬂux, (Fig. 9) (25–26). It was rationalized
that, in addition to a lower pKa, the ﬂuorine atom forms a weak
internal H-bond with the exocyclic nitrogen of the amidine, which
is beneﬁcial for both permeability and Pgp efﬂux. Nevertheless,24, BACE1 IC50 = 32 nM
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D. Oehlrich et al. / Bioorg. Med. Chem. Lett. 24 (2014) 2033–2045 2037this modiﬁcation increased the afﬁnity for the hERG ion channel.
Addition of a lipophilic electron-withdrawing group in the
2-position of the pyridyl ring such as diﬂuoromethyl group, low-
ered the hERG liability and further ﬁne-tuned other properties.
Inhibitor 27 (AZD-3839), based on its preclinical proﬁle, was pro-
gressed into phase I clinical trials (Fig. 10).43
Recently, AstraZeneca highlighted their interest in a class of
double spiro amino-imidazoles, with the publication of a process
patent describing the large scale synthesis of a camsylate salt of
28.45,46 This series of compounds arises from the introduction of
a spiro substituent to the warhead, nearly identical to the modiﬁ-
cation previously performed by Vitae Pharmaceuticals on the
hydantoin warhead 21, (Fig. 7).42
Schering–Plough arrived at the same amino-hydantoin 12 as
identiﬁed by Wyeth via modiﬁcation of their isothiourea fragment
hit 2, obtained via NMR screening.27 Optimization of this series30, BACE1 Ki = 670 nM
Cell Aβ40 IC50 = 460 nM
12, BACE1 Ki = 3.
31, BACE1
Cell Aβ40 I
F = 69%
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Figure 1identiﬁed 29, with an enzymatic IC50 of 5.4 nM and a cellular
IC50 of 82 nM, which also lowered Ab40 in vivo (Fig. 11).47
It was hypothesized that molecules with slightly higher basicity
than the aminohydantoins (pKa  7) would accumulate in the
endosomes, and result in a higher cellular and thus in vivo
potency.48 To achieve this, they expanded the ring into a slightly
more basic six-membered amino-dihydropyrimidinone, arriving
at a series previously explored by AstraZeneca, (9, Fig. 4).31,48 How-
ever, the addition of one sp3 carbon has an effect on the shape of
the ring and thus the possible vectors into the enzyme pockets.
In the ﬁve-membered aminohydantoins one of the groups of the
quaternary center protrudes into the P20 pocket (cyclopropyl group
in 29). In the amino-dihydropyrimidines series this group projects
towards Ile118. As a result, only small substituents, like methyl, are
tolerated.48 In addition, the biaryl substituent of the amino-
dihydropyrimidinone needs to be in a pseudo axial conformation
to occupy the P1/P3 pocket. Amino-dihydropyrimidinone 30
exhibits moderate activity towards BACE1. Subsequent modiﬁca-
tion of the biaryl ring system to optimally occupy the P1 and P3
pocket, delivered highly active analogue 31 with an oral bioavail-
ability of 69%, good permeability, an efﬂux ratio of 2.4 and an
average brain/plasma ratio of 3 (Fig. 11).48,49
In an effort to boost the potency and access the P20 pocket,
Merck designed a series of conformationally constrained bicyclic-
amino-dihydropyrimidinones.50 Computationally aided design
directed them to the series of pyrrolidine fused bicycles. The
pyrrolidine nitrogen provided the optimal trajectory for the explo-
ration of the P20 pocket, which resulted in the identiﬁcation of
compounds such as 32–34 (Fig. 12).50,51 By optimally substituting
the pyrimidine and thus ﬁlling the P20 pocket as in the case of 34,
Merck was able to remove the P3 substituent and maintain good
potency.517 μM
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2038 D. Oehlrich et al. / Bioorg. Med. Chem. Lett. 24 (2014) 2033–2045The amino-dihydropyrimidinones were selected for their favor-
able pKa range and their potential drugability. However, Merck also
reported a modiﬁcation of this series where the aminothiadiazine
dioxide group was used as an isosteric replacement for the ami-
no-dihydropyrimidinones. In this series, the sulfonamide was used
to modulate the basicity of the amidine, while promoting good
bioavailability and ligand afﬁnity. Comparative data described
show that the amino-thiadiazole oxides exhibit similar BACE1
afﬁnity with a reduced Pgp efﬂux liability versus their amino-
dihydropyrimidinone analogs (Fig. 13).49,52
Eli Lilly identiﬁed isothiourea hits 3 and 4 in a fragment-based
screening assay of approximately 8000 fragments (Fig. 14).28 The
original amino-benzothiazine 4was a rigid bicyclic structure with-
out a suitable vector into the P1/P3 region. Elimination of fused
aromatic ring in 4 and subsequent substitution of newly formed
sp3 carbon resulted in the identiﬁcation of amino-dihydrothiazine
37 with a 36-fold increase in potency. The phenyl ring of 374, BACE1 IC50 = 790 μM3, BACE1 IC50 = 8200 μM 3
S
NH
NNH2 NH2
S
N
Figure 1occupies the P1 region and could be extended into the P3 pocket
by substitution at the meta-position, resulting in sub-micro molar
potency. Deactivation of the metabolically labile central aryl ring
with ﬂuorine atoms gave 38 (LY-2811376) (Fig. 14). This was the
ﬁrst BACE1 inhibitor of this amidine class to reach phase I clinical
trials and showed prominent and long-lasting Ab reductions in
lumbar CSF after oral dosing of 30 and 90 mg in healthy volun-
teers.28 Because of off-target retinal pathology, identiﬁed in long
term preclinical toxicology studies, this compound was discontin-
ued from further clinical evaluation.28 Nevertheless, it showed the
ﬁrst evidence of a dose-dependent reduction of CSF APPb in the
human CNS by a BACE1 inhibitor and thus strengthened the theory
of BACE1 being a promising target for treatment of AD.30
Already in 2007 Shionogi described BACE1 inhibitors with the
same amino-dihydrothiazine warhead as used by Eli Lilly.29 Inter-
estingly Shionogi were the ﬁrst to disclose the use of an amide
linker between the two aryl rings as exempliﬁed by 39 to 41
Figure 15. This linker resulted in a considerable boost in potency38, BACE1 IC50 = 240 nM
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D. Oehlrich et al. / Bioorg. Med. Chem. Lett. 24 (2014) 2033–2045 2039when compared to the bis-aryl system. This boost is due to the for-
mation of a favorable H-bond between the NH of the ligand and the
carbonyl oxygen of back bone Gly291.28 Since the disclosure of this
series, many R&D programs have incorporated these amide linkers
into their series. Shionogi explored many amide-linked aromatic
and alkylic systems, as exempliﬁed by 40 and 41, Figure 15.29,53–55
Shionogi also explored amine-linked bis-aryl-aminodihydrothi-
azine systems.56 Contrary to the previous amide-linked systems,
most P3 heteroaryl rings were substituted at the ortho-position
(Fig. 16). In general, this modiﬁcation appears a little less potent
in vitro than the corresponding amide linked P1/P3 substituents.
While six-membered amino-dihydrothiazines were highly
potent BACE1 inhibitors, ﬁve-membered analogues such as 447, Cell IC50 = 41.2 μM 49, BACE1 X = H;  Cell IC50 
      BACE2 X = H; Cell IC50 =
50, BACE1 X = F; Cell IC50 =
      BACE2 X = F; Cell IC50 =
NH 2
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Figure 1demonstrated only moderate potency (Fig. 16).57 Shionogi also ex-
plored modiﬁed versions of the cyclic isothiourea warhead with
the introduction of endo- or exo-cyclic double bonds and additional
ring fusions (Fig. 16).57,58
Replacement of sulfur with oxygen led to amino-dihydro-1,3-
oxazines cores (46), a warhead which also appears in patent
applications from multiple companies.59 Eisai and Shionogi further
reﬁned both thiazine and oxazine series to explore bicyclic ver-
sions such as 47.60,61 Interestingly these are analogous to the bicy-
clic amino-dihydro-1,3-thiazines cores described by Eisai (Fig. 19,
53 and 54) and Eli Lilly (Fig. 22 and 62) vide infra. In addition to
monocyclic amino-dihydro-1,3-oxazine warhead, Roche also de-
scribed alternatively fused bicyclic derivatives, represented by
48.62,63 They further decorated the fused cyclo-pentane with a
gem-diﬂuoro functional group, supposedly to modulate the pKa of
the system.
Roche’s investigation was initiated by the identiﬁcation of a
dihydrothiazine HTS hit (7, Fig. 3).28 Modiﬁcations of the warhead
allowed them to optimise physiochemical properties, such as pKa,
logD, solubility and permeability.63 Their exploration showed that
exceedingly basic compounds resulted in low activity in vivo,
which was attributed to low exposure (Fig. 18).
Roche also identiﬁed a series of seven-membered cyclopropyl-
fused 1,3-thiazepines.64 It is speculated that the fusion of the
cyclo-propyl alters the bond angles, and thus has an effect of the
orientation of groups in the P1 and P3 pockets. It also has an effect
on the pKa of the amino-thiazine functional group due to the elec-
tron-withdrawing properties of the cyclopropyl ring, resulting
from its enhanced p-character (49, pKa = 8.9). Interestingly, the
introduction of a ﬂuorine atom to the P1 phenyl results in a marked
decrease in potency, which is perhaps due to steric clash between
the cyclopropyl and the introduced ﬂuorine. This series of com-
pounds shows greater potency for BACE2 than for BACE1.64
Eisai described several series of bicyclic aminodihydrothiazines
fused with unsaturated ﬁve- and six-membered rings, exhibiting
high afﬁnities for BACE1 (Fig. 19).65–67
Eisai recently published two process patent applications that
highlighted warheads (55–57) and P3 substituents (58) of interest
(Fig. 20).68,69 It is possible that a combination of one of these war-
heads with 58 represents their clinical candidate, for example 59.
Eisai further took advantage of the properties of the amino-
dihydropyrimidinones integrating a ring fusion which incorporates
a substituted tetrahydrofuran as in 60 (Fig. 21).70 Merck applied
the previously discussed replacement of the amino-dihydropyri-
midinones with iminothiadiazine dioxides, to explore a series of
analogous bicyclic derivatives exempliﬁed by 61.71
Similar to Eisai and Shionogi, Eli Lilly also explored a series of
fused aminodihydrothiazine derivatives, which resulted in their51, BACE1 X = H;  Cell IC50 = 31 nM
      BACE2 X = H; Cell IC50 = 1 nM
52, BACE1 X = F; Cell IC50 = 60 nM
      BACE2 X = F; Cell IC50 = 5 nM
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54, BACE1 IC50 = 6 nM
Rat brain Aβ40 = -72% @ 10 mg/Kg po, 6h
Rat CSF Aβ40 = -74% @ 10 mg/Kg po, 6h
[Plasma] = 229 nM, 6h 
[Brain] = 845 nM, 6h
B/P ratio = 3.7 
Pgp efflux = 1.7
53, BACE1 IC50 = 7 nM
Rat brain Aβ40 = -64% @ 10 mg/Kg po, 6h
Rat CSF Aβ40 = -70% @ 10 mg/Kg po, 6h
[Plasma] = 570 nM, 6h 
[Brain] = 570 nM, 6h
B/P = 0.7 
Pgp efflux = 20.7
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2040 D. Oehlrich et al. / Bioorg. Med. Chem. Lett. 24 (2014) 2033–2045second BACE1 inhibitor tested in the clinic, 62 (LY-2886721).72 In
June 2013 the clinical investigation of this compound was stopped
due to abnormal liver function; the company’s press release sug-
gests that this is not target mediated so interest in the target
remains.73
Pﬁzer also described some bicyclic aminodihydrothiazine deriv-
atives, however in their examples the pyran ring was substituted
with a heteroaromatic, such as isoxazole in 63 (Fig. 23).74 This
additional substitution apparently boosted the potency sufﬁciently
to allow truncation of the molecule and removal of the P3 substi-
tuent. This had a favorable effect on the TPSA of the system and
as a consequence may enhance permeability.
Further to the 1,3-oxazine warhead (Fig. 17), the 1,4-oxazine
warhead has been independently exempliﬁed in various patent
applications and publications by Janssen,75 Novartis,76 Roche77and AstraZeneca.25 Based on the ﬁling dates of the various applica-
tions, the investigations were ongoing simultaneously. The P1/P3
investigations scan all chemical space and examples of amide
(64),77 amino linked (65)78 and directly linked (66)79 P1/P3 sys-
tems are described in the various patents (Fig. 24). Roche pub-
lished a broad exploration of 1,4-oxazines investigating both the
six- and seven-membered systems. They seem to concentrate their
efforts on seven-membered systems, in which they explore many
substitution patterns on the warhead.80
Analogously to their work on the seven-membered cyclopropyl-
fused-1,3-thiazepine Roche also explored cyclopropyl-fused-1,4-
homo-oxazepine (Fig. 25).64,81 However, the seven-membered
cyclopropyl-fused-1,3-thiazepine are more potent against BACE1
than the oxygen analogs in cell based assays (50, IC50 = 26 nM,
67, IC50 = 73 nM). Interestingly the oxygen analogs showed an in-
versed selectivity over BACE2 compared to the amino-thiazine
analog 50. Other substitution patterns have been explored as
63, BACE1  IC50 =  59 nM
BACE2  IC50 = 4.55μM 
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D. Oehlrich et al. / Bioorg. Med. Chem. Lett. 24 (2014) 2033–2045 2041exempliﬁed by 68–70. Efforts seem to concentrate around smaller
electron-withdrawing substituents, which is presumably to control
the pKa of the amidine, which for 69 has been measured at a pKa
>10.63
Novartis and Janssen concentrated their research efforts on six-
membered 1,4-oxazine derivatives. Interestingly, they both focus
on electron withdrawing substituents which may have a positive
effect over the pKa of the amidine (Fig. 26).82
Novartis explored the addition of placing ﬂuorine atoms on the
quaternary methyl, presumably in an attempt to modulate the pKa
of the system. Interestingly the mono-ﬂuoro-methyl (72) and the
diﬂuoromethyl (73) are more potent that the corresponding
methyl analog (71), while the triﬂuoromethyl derivative (74) is less
potent.
Novartis explored other ways to control the pKa of the amidine,
one other example is the introduction of a CF3 alpha to the amidine
as in 75–77.82,83 Compound 75 is also the subject of a recent pro-
cess patent for the isolation of a crystalline derivative, which sug-
gests a high level of interest in this particular molecule.84
Janssen’s patent applications concentrate on the introduction of
electron withdrawing groups on the morpholino 6-position to
modulate the pKa of the system. Their modiﬁcations include the64, BACE1 IC50 = 120 nM 65, BACE1 IC5
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Figure 2addition of mono-ﬂuorine 78, diﬂuoromethyl 79, triﬂuoromethyl
80 and also triﬂuoromethyls and ﬂuorine combined as in 81.85,86
Novartis disclosed a potent series of BACE1 inhibitors based on
a tetrahydropyrazine warhead (82, Fig. 27).87 The addition of a car-
bonyl to this system was investigated by Janssen and Novartis,87–89
with representative examples 84–85 from Janssen in Figure 27.90
In an attempt to improve the properties of their initial series of
2-amino-3,4-dihydroquinazolines 83 which exhibited high lipo-
philicity and basicity, they adopted an in silico virtual screen to
triage de novo ideas. This led to the identiﬁcation of the two
regio-isomeric forms of the piperazinone warhead 84 and 85.
Predicted and measured pKa values were found to be consistent
with the required protonation at the site of action.
Janssen continued their interest in piperazine warheads and
published several patent applications around piperazine deriva-
tives fused to ﬁve-membered electron deﬁcient heteroaromatics
86–87 (Fig. 28).91,92 Shionogi and Schering also explored the intro-
duction of an electron deﬁcient heteroaromatic ring, however their
respective series fuse the ring to an amino-dihydropyrimidine war-
head, with representative structure 88 shown below.93,94
As yet another morpholino alternative, Merck reported a series
of oxidized thio-1,4-oxazine cores 89–90 where the electron with-
drawing sulfone group will result in a reduction in pKa of the ami-
dine.95,96 It appears that to optimize for potency, the substitutes on
the C-6 position should be limited to smaller groups. In essence,
this can also be considered a modiﬁcation of the previously de-
scribed iminothiadiazine dioxides warhead, exempliﬁed by 91.
This compound is speciﬁcally claimed in WO-2011/044181 and
may well represent or resemble the structure of MK-8931
(Fig. 29).49
Chronologically, the warhead motif has increased in complex-
ity, looking for ever more inventive ways to combine the properties
required for high BACE1 afﬁnity, while not infringing on the
intellectual space of another. This has been made necessary by
the limited chemical space available for potent BACE1 inhibitors66, BACE1 IC50 = 710 nM0 = 580 nM
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75,  X = CH, Y = CH
BACE1  IC50 = 10 nM
80, BACE1  
IC50 = 34 nM
73, BACE1 
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78, BACE1 
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D. Oehlrich et al. / Bioorg. Med. Chem. Lett. 24 (2014) 2033–2045 2043and the high level of activity within the ﬁeld. Figure 30 gives an
overview of the chemo-types explored and the companies involved
in their exploration. While not exhaustive, it gives an idea of the
competitiveness of the ﬁeld and the overlap between various
R&D investigations.
The need for an amidine-based functional group in this class of
BACE1 inhibitors has created its own unique challengers for devel-
opment, including Pgp and hERG. The basic center is required for
the afﬁnity to the catalytic dyad and as such needs to be proton-
ated at the site of action. Chronologically, through the various
R&D investigations we have seen the modulation of this basic cen-
ter in ever more inventive ways, while maintaining the possibility
to protonate as required.
All non-peptidomimetic small molecule BACE1 inhibitors have
had to deal with the very large active site. The class of inhibitors
described in this review has delivered the optimal vectors, aided
by structure based design. This led to the discovery of the quater-
nary center and the possibility to ﬁll/explore the P1/P3 and the P20
pockets optimally. The identiﬁcation of the H-bond with Gly291,
created by the amide linker between the P1 and P3 substituents
led to a boost in potency. The need to combine all these compo-
nents has led to compounds with TPSA’s close to and above
100 Å.2 Nevertheless, many of them have demonstrated good per-
meability and brain penetration. This may be explained by the
masking of the amide polar surface area by an intra-molecular
hydrogen bond with the nitrogen of the heterocycle P3 targeting
substituent.97Janssen
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Figure 3In general, the selectivity of this amidine based class of BACE1
inhibitors over similar proteases such as cathepsin D and E, renin,
and pepsin has been reported to be excellent. On the other hand,
selectivity over the more homologous BACE2 enzyme appears to
be more difﬁcult to achieve, and many are reported to have the
same level of potency for BACE1 and BACE2. BACE2 has recently
been identiﬁed as being involved in the regulation of pancreatic
b cell mass and function and BACE2 inhibition has been postulated
as a mechanism to treat Type II diabetes.55 BACE2 has also been
recognized as an efﬁcient Ab protease.98 BACE2 has further been
identiﬁed to play a role in the processing of pigment cell-speciﬁc
Melanocyte Protein (PMEL), revealing the importance of BACE2 in
pigmentation.99 These roles for BACE2 may hint to possible toxic
consequences of chronic, non-selective BACE1 inhibition.
While BACE1 inhibition clearly results in reduced formation of
Ab, investigations are also ongoing to understand the possible toxic
consequences of BACE1 inhibition itself. Initial reports suggested
the existence of a subtle phenotype for the BACE1 KO animals,
which reinforced the attraction of BACE1 inhibition as a therapy
for AD.100–104 However, the identiﬁcation of more than 60 BACE1
substrates including neuregulin, cast doubt on these preliminary
observations.105,106 Neuregulin-1 or at least the Ig-containing b1
NRG1 (IgNrgb1) isoform, has been identiﬁed as a substrate for
BACE1. It has been found to regulate the muscle spindle physiology
and maintain motor coordination.106 It is thus possible that ex-
tended inhibition of BACE1 may result in disrupted muscle spindle
functions and may lead to impaired movement.106 Cai et al.RocheAstraZenecaZeneca A = C or O.
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2044 D. Oehlrich et al. / Bioorg. Med. Chem. Lett. 24 (2014) 2033–2045described retinal pathology resulting from BACE1 inhibition.107
The retinal toxicity observed in BACE1 KO mice includes retinal
thinning, vascular abnormalities and an increase in age pigment.
These critical ﬁndings and the fact that BACE1 inhibitors will need
to be chronically dosed, highlight the need to monitor for adverse
toxicity during the development of BACE1 inhibitors and the deter-
mination of a therapeutic window.
While it may be possible to design an orthosteric BACE1 inhib-
itor with selectivity over BACE2, substrate, that is APP, selectivity
may not be possible with an orthosteric inhibitor, especially one
whose binding mode is associated to the catalytic dyad. Novel
modes of modulation of BACE1 activity may be required to selec-
tively target APP processing.
This latest generation of BACE1 inhibitors has clearly been more
successful and achieved more advanced milestones, than the ear-
lier incarnations. Of this generation of BACE1 inhibitors seven have
successfully reached clinical analysis. There have been some
failures as with the two compounds from Eli Lilly (LY-2811376 &
LY-2886721), AZD-3839 from AstraZeneca vide supra, and
RG-7129 from Roche which was recently terminated in phase I.
Many other companies still have BACE1 inhibitors undergoing clin-
ical analysis. The most advanced of these is MK-8931 from Merck,
which has started recruiting for the phase III trial in prodromal and
mild to moderate AD in patients from 55 to 85 years old.108 Should
the readout of MK-8931 be successful, Merck will likely have the
ﬁrst oral disease modifying therapeutic for mild to moderate
Alzheimer’s disease. Merck is not alone in the clinic and is followed
by compounds from Eisai (E2609) and AstraZeneca (AZD-3293).
Presumably, after the successful data generated during the various
phase I clinical trials, Eisai will imminently start their phase II anal-
ysis of E2609. Eisai is currently analyzing the metabolism and
elimination in an open label single dose of [14C]-E2609, in healthy
volunteers.109 AstraZeneca is progressing AZD-3293 through sev-
eral phase I trials, of which the ﬁrst has been completed. They
are currently recruiting for two phase I clinical trials to assess
the effect of cytochrome 3A4 inhibitors on the pharmacokinetics
of AZD-3293 in healthy volunteers, and to assess the safety and
effect of AZD-3293 in healthy elderly and AD patients.110,111
The results of these clinical trials may validate not only the
amyloid hypothesis but also whether extended inhibition of BACE1
is therapeutically viable as a treatment of AD. Questions to be
answered by these trials will be the required level of BACE1
inhibition, and the optimal moment of intervention in the disease
progression. Future BACE1 inhibitors are likely to require a better
proﬁle, being more selective for not only BACE1 but also APP.
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